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Alcohol liver disease (ALD) is one of the major chronic liver diseases worldwide, ranging from fatty liver, alcoholic hepati-
tis, cirrhosis, and potentially, hepatocellular carcinoma. Epidemiological studies suggest a potential link between ALD and
impaired circadian rhythms, but the role of hepatic circadian proteins in the pathogenesis of ALD remains unknown.
Here we show that the circadian clock protein BMAL1 in hepatocytes is both necessary and sufficient to protect mice
from ALD. Ethanol diet-fed mice with liver-specific knockout (Bmal1-LKO) or depletion of Bmal1 develop more severe
liver steatosis and injury as well as a simultaneous suppression of both de novo lipogenesis and fatty acid oxidation, which
can be rescued by the supplementation of synthetic PPARa ligands. Restoring de novo lipogenesis in the liver of Bmal1-
LKO mice by constitutively active AKT not only elevates hepatic fatty acid oxidation but also alleviates ethanol-induced
fatty liver and liver injury. Furthermore, hepatic over-expression of lipogenic transcription factor ChREBP, but not
SREBP-1c, in the liver of Bmal1-LKO mice also increases fatty acid oxidation and partially reduces ethanol-induced fatty
liver  and liver  injury. protective role of BMAL1 in hepatocytes against ALD. The protec-
tive action of BMAL1 during alcohol consumption depends on its ability to couple ChREBP-induced de novo lipogenesis
with PPARa-mediated fatty oxidation. (HEPATOLOGY 2018; 68:883-896).
A
lcohol over-consumption is the primary cause
of liver-related mortality in western countries.
In the United States, more than 50% of the
population consumes alcohol.(1,2) As the primary site
of alcohol metabolism, the liver is a major target organ
of alcohol-induced injury. Three in 10 adults are heavy
alcohol drinkers with a high risk for alcoholic liver dis-
ease (ALD).(3) ALD covers a spectrum of disease
states that range from simple liver steatosis (fatty liver),
steatohepatitis (combined with inflammation), to
fibrosis and/or cirrhosis.(3) Both genetics and
environmental factors contribute to the progression of
ALD. Particularly, mice with circadian disruption have
been reported to have a higher permeability of intesti-
nal epithelial barrier, a risk factor of alcoholic tissue
damage.(4) Human studies also indicated that night
workers with circadian misalignment are susceptible to
alcohol-induced intestinal hyperpermeability with
social drinking.(5) Although these observations point
to a possible role of impairment of circadian rhythms
in the pathogenesis of ALD, what and how circadian
proteins are involved in ALD remain largely unknown.
Abbreviations: AKT2-CA, constitutively active AKT2; ALD, Alcohol liver disease; ALT, alanine aminotransferase; EM, electron microscope; HFD,
high-fat diet; LKO, liver-specific knockout; MKO, macrophage-specific knockout; TG, triglycerides; WT, wildtype.
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 Conclusion:  we  identified  a
The circadian clock functions in the majority of cell
types in the human body. In hepatocytes, BMAL1
is one of the essential components of the circadian
clock that drives the cyclic expression of a variety of
metabolic genes involved in lipid, glucose, and choles-
terol metabolism.(6) We previously discovered that
BMAL1 is also essential for maintaining insulin
responsiveness in the liver. A Bmal1 deficiency severely
blunts insulin-stimulated AKT phosphorylation and
reduces insulin-stimulated de novo lipogenesis.(7) Upon
chronic HFD feeding, hepatic Bmal1 deficiency results
in severe insulin resistance and liver steatosis,(8) indi-
cating that impairment of BMAL1 expression or func-
tion may contribute to chronic liver metabolic diseases.
Alcohol exposure has been shown to impair lipid
homeostasis in hepatocytes and cause liver injury dur-
ing the development of ALD.(3) It has been reported
that ethanol feeding increases SREBP-1c-driven de
novo lipogenesis while inhibiting the PPARa activity
in the liver.(9-11) Administration of a synthetic PPARa
agonist reverses alcoholic fatty liver and improves liver
function in mice.(9) The inhibitory effect of ethanol on
the PPARa transcriptional activity was observed in
cultured hepatocytes, suggesting that ethanol and its
metabolites could impact the DNA-binding activity of
PPARa in the liver.(10) Currently, it remains unclear
how ethanol feeding alters the hepatic PPARa activity.
Given the pivotal role of PPARa in liver lipid
homeostasis, extensive research has been done on how
the PPARa activity is modulated in response to hor-
monal and nutritional signals. Unexpectedly, the
PPARa activity is severely down-regulated in hepato-
cytes lacking FASN, indicating an intricate link
between de novo lipogenesis and the biogenesis of
endogenous PPARa ligands and the subsequent
PPARa activation in the liver.(12) Follow-up studies
show de novo lipogenesis is a major source of
phosphatidyl-choline in hepatocytes that serves as
endogenous ligands for PPARa.(13) However, how the
connection between de novo lipogenesis and PPARa
activation is regulated during ethanol feeding has not
been tested. In this study, we explored the role of a key
circadian protein BMAL1 in alcoholic liver disease
using both hepatocyte-specific gain and loss of func-
tion models. Our findings suggest that in hepatocytes,
BMAL1 is critical for reducing liver steatosis and
hepatocyte apoptosis during chronic alcohol feeding.
Moreover, BMAL1 is required for maintaining the
PPARa activity in hepatocytes partially via its ability to
promote ChREBP-induced de novo lipogenesis.
Materials and Methods
ANIMAL EXPERIMENTS
All animal experiments were approved by the Institu-
tional Animal Care and Research Advisory Committee
at the University of Michigan. All animal care and use
were in accordance with guidelines of the University of
Michigan Institutional Animal Care and Use Commit-
tee. C57BL/6 mice were maintained on 12 hour/12 hour
light/dark cycles with ad libitum access to food and water.
Bmal1Flox/Flox mice were generously provided by Dr.
Jiandie Lin at the University of Michigan. Bmal1 liver
specific knockout (Bmal1-LKO) mice were generated by
crossing Bmal1Flox/Flox mice with Albumin-Cre mice.
Ethanol diet feeding and binge was performed with the
protocol described previously.(14) For fenofibrate treat-
ment, the mice were daily gavaged in the last 8 days of
ethanol diet feeding (20mg/kg body weight). For liver-
specific knockdown or overexpression, AdshLacZ vs.
Ad-shBmal1, Ad-GFP vs. Ad-Flag-Bmal1, Ad-Akt2-
CA or Ad-Flag-Chrebp adenoviruses were delivered via
tail vein injection at a dose of 1x1012 plaque-forming
units on the first day of ethanol diet feeding.
ELECTRON MICROSCOPY
Mouse liver was excised, minced into small pieces and
fixed in a solution of 2% paraformaldehyde and 2%
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glutaraldehyde in PBS for 2 hours at room temperature.
After washing in PBS, the tissue samples were post fixed
in osmium tetroxide for 45 minutes at room tempera-
ture. Dehydration of the samples was accomplished by
transferring the samples through a series of graded etha-
nol and then 100% propylene oxide. The tissue was then
infiltrated by transferring the samples into increasing
concentrations of Epon to propylene oxide solutions at
1:3, 1:1, 3:1, and then 100% Epon and finally embed-
ded. Sections were made with a Leica EM UC7 ultra-
microtome (Leica), stained for 15 minutes with 7%
(saturated) aqueous uranyl acetate, washed, stained with
lead citrate, and examined with a JEOL JEM 1400 plus
transmission electron microscope (JEOL USA).
STATISTICS
Statistical analysis was performed using Prism ver-
sion 6.0 (GraphPad Software, San Diego, CA). Statis-
tical significance was determined either by unpaired
two-tailed Student’s t-test for comparison between two
groups or by one-way ANOVA with Tukey’s or Dun-
nett’s post-hoc test for multiple group comparison. All
results were given as the mean 6 SEM. Results were
considered statistically significant with p value < 0.05.
Other detailed methods, including adenoviral produc-
tion, serum ALT, liver histology, Nile Red staining,
MPO staining, sucrose gradient sedimentation, TUNEL
staining, liver triglycerides assay, primary mouse hepato-
cytes isolation and culture, cDNA synthesis and RT-




SENSITIZES MICE TO ETHANOL
FEEDING-INDUCED LIVER
STEATOSIS AND LIVER INJURY
To study the role of hepatic molecular circadian
clock in the pathogenesis of ALD, we adopted the
chronic-plus-binge feeding described by the Gao
group to create a moderate ALD in mice.(14) Wildtype
(WT) mice were fed a 5% ethanol diet for 10 days
before binged with 5g ethanol per kg body weight at
Zeitgeber time 3, and dissected 9 hours later. Ethanol
feeding significantly increased liver triglycerides accu-
mulation (Supporting Fig. S1A,B), ALT levels and
Cyp2e1 expression level (Supporting Fig. S1C,D)
along with enhanced expression of pro-inflammatory
cytokines, ER stress and pro-apoptotic markers (Sup-
porting Fig. S1E-G), as well as increased neutrophil
recruitment (Supporting Fig. S1H), indicating that
this chronic-plus-binge ethanol regimen induces mild
to moderate liver steatosis and injury in WT mice.
We also observed enhanced acetylation of p65, a
direct target of SIRT1,(15) in the liver of ethanol-fed
mouse livers, indicative of potent suppression of the
SIRT1 activity by ethanol feeding. However, ethanol
feeding showed no effect on the abundance of SIRT1
(Supporting Fig. S2A,B). Given the important role of
SIRT1 in regulating hepatic circadian clock,(16-19) we
hypothesize that ethanol feeding could impact the circa-
dian clock in the liver through SIRT1 inhibition. We
found the diurnal rhythms ofDbp and Per1, two classical
clock genes, were lost in the ethanol-fed liver (Support-
ing Fig. S2C). At the protein level, ethanol feeding led
to an increase in both BMAL1 and CLOCK protein,
but a reduction of AKT-PS473 in the liver (Supporting
Fig. S2A,B). We previously showed that SIRT1 protects
the BMAL1-CLOCK protein complex formation in
the presence of palmitate in hepatocytes.(19) To test
whether ethanol could impact the BMAL1-CLOCK
interaction, we performed anti-FLAG immunoprecipi-
tation in ethanol-treated primary mouse hepatocytes
transduced with Ad-Flag-Bmal1 vs. Ad-GFP. We
detected a strong interaction between FLAG-tagged
BMAL1 and the endogenous CLOCK in vehicle-
treated cells. However, the BMAL1-CLOCK interac-
tion was weakened by ethanol treatment (Supporting
Fig. S2D). To test whether ethanol feeding impairs the
BMAL1-CLOCK complex in mouse liver, we per-
formed sucrose gradient sedimentation using nuclear
extracts isolated from both control diet-fed and ethanol
diet-fed liver tissues. Consistent with in vitro findings,
ethanol feeding reduced the number of fractions in
which BMAL1 and CLOCK protein co-migrated
(Supporting Fig. S2E). In summary, ethanol diet indu-
ces selective impairment of the hepatic circadian clock
activity, in addition to liver steatosis and liver injury.
To evaluate the role of an intact molecular clock in
hepatocytes during ALD, we subjected Bmal1flox/fox
and Bmal1 liver-specific knockout (Bmal1-LKO) to the
ethanol diet/binge model. Compared with Bmal1flox/fox
control, Bmal1-LKO mice quickly lost weight on
ethanol diet (Supporting Fig. SF3A), accumulated
more lipids in the liver (Fig. 1A,B), developed more
pronounced liver injury (Fig. 1C), and hepatocyte apo-
ptosis by TUNEL staining and keratin 18 cleavage
(Fig. 1D,E). However, increased liver injury in Bmal1-
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LKO liver was independent of gene expression of
Cyp2e1 and markers of oxidative stress, ER stress,
inflammation, and apoptosis (Supporting Fig. S3B-F).
Neutrophil infiltration was comparable between
Bmal1flox/fox and Bmal1-LKOmice (Supporting Fig. S3G).
Mitochondrial dysfunction has been implicated in the
pathogenesis of ALD.(20) The liver of mice with hepato-
cyte deficiency in Bmal1 showed a defect in mitochon-
drial fission following a 40-wk high-fat diet.(8) To test
whether Bmal1-LKO mice also exhibited mitochondrial
defects, we evaluated the mitochondrial morphology in
the liver of Bmal1flox/fox vs. Bmal1-LKO mice with elec-
tron microscopy after ethanol feeding. In the Bmal1flox/fox
liver, mitochondria displayed normal shape and active fis-
sion. However, we observed swollen mitochondria
without fission in the liver of Bmal1-LKO after ethanol
diet (Fig. 1F). In summary, Bmal1 deficiency in hepato-
cytes results in augmented liver steatosis and liver injury
with mitochondrial impairment following ethanol diet
independently of ER stress, oxidative stress, and induc-
tion of pro-apoptotic genes.
MICE WITH ACUTE DEPLETION
OF Bmal1 IN HEPATOCYTES ARE
MORE SUSCEPTIBLE TO
ETHANOL-INDUCED FATTY
LIVER AND LIVER INJURY
To test how acute depletion of hepatic Bmal1 in adult
mice responds to ethanol feeding, we knocked down
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FIG. 1. Hepatocyte-specific Bmal1 knockout mice are sensitive to ethanol feeding-induced liver steatosis and liver injury. Eight-
week-old Bmal1Flox/Flox littermates and Bmal1Flox/Flox Alb-Cre(1) (Bmal1-LKO) mice were fed 5% ethanol diet for 10 days before
binge feeding with ethanol (5 g/kg body weight) at Zeitgeber Time (ZT)3 and dissected 9 hours later (n 5 4 for Bmal1Flox/Flox and
n 5 5 for Bmal1-LKO, both male and females). (A) Hepatic triglyceride levels. (B) H&E staining and Nile red staining. (C) ALT
assay to assess liver injury. (D) TUNEL staining and immune-fluorescence against cleaved caspase3 to assess apoptosis. (E) Western
blotting analysis of hepatic apoptotic markers. (F) Transmission electron microscopy (magnification 40,000X). Mitochondria undergo-
ing fission are indicated with green arrowheads and swollen mitochondrial with red arrowheads. *p < 0.05, **p < 0.01 by two-tailed
Student’s t test. Scale bar 5 100 lM for B and D; Scale bar 5 400 nM for F.
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hepatic Bmal1 in adult WT mice by administrating Ad-
shBmal1 via tail vein prior to ethanol feeding. Com-
pared with Ad-shLacZ control, Ad-shBmal1-injected
mice showed negative gain in body weight (Supporting
Fig. S4A) but greater liver lipid accumulation (Fig.
2A,B) by liver triglycerides assay and Nile Red staining.
Liver H&E staining also revealed increased lipid drop-
lets in the liver of Ad-shBmal1 mice (Fig. 2B). Serum
ALT assay detected greater liver injury in the mice of
Ad-shBmal1 (Fig. 2C), which was further supported by
a significant increase in hepatocyte apoptosis detected
by TUNEL staining, caspase 3 staining, and immuno-
blotting for apoptotic markers including cleaved keratin
18 and caspase 3 (Fig. 2D,E). Interestingly, acute
Bmal1 knockdown did not result in altered expression
of Cyp2e1, markers of inflammation, ER stress, and
apoptosis (Supporting Fig. S4B-F). Altogether, our
data suggest that acute hepatic clock deficiency by
depleting Bmal1 also sensitizes mice to ethanol-induced




A significant body of work has established the criti-
cal role of macrophage activation in the pathogenesis
of ALD.(21,22) The circadian clock is also present in
macrophages and plays an important role in regulating
inflammatory cytokine production.(23) We hypothe-
sized that deletion of Bmal1 in macrophages may also
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FIG. 2. Adult-onset hepatocyte Bmal1 depletion sensitizes mice to ethanol-induced fatty liver and liver injury. Eight-week-old mice
were injected with either adenovirus expressing shRNA targeting Bmal1 (Ad-shBmal1, n 58) or Ad-shLacZ control (n 55) at MOI
1x1012 pfu, fed 5% ethanol diet for 10 days and then binged with ethanol (5 g/kg body weight) at ZT 3 of the eleventh day and were
dissected 9 hours later. Liver samples were subjected to triglyceride assay (A), H&E staining and Nile Red staining (B) to assess
hepatic lipid accumulation, ALT assay to assess liver injury (C), TUNEL staining and caspase3 immuno-staining to assess apoptosis
(D), and Western analysis of apoptotic markers (E). *p < 0.05, **p < 0.01 by two-tailed Student’s t test. Scale bar 5 100 uM.
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impact the severity of ALD in mice. We therefore
generated macrophage-specific deletion of Bmal1
(Bmal1-MKO) with Lysosome-Cre and confirmed that
the BMAL1 protein was largely absent in liver resi-
dential macrophages Kupffer cells isolated from
Bmal1-MKO livers (Supporting Fig. S5A). Following
ethanol feeding protocol, both Bmal1flox/flox and
Bmal1-MKO displayed similar body weight, liver
TAG and lipid droplet formation by H&E staining
and Oil-Red-O staining (Supporting Fig. S5B-D).
We also detected comparable levels of serum ALT
between Bmal1flox/flox and Bmal1-MKO mice (Support-
ing Fig. S5E). EM showed intact mitochondrial mor-
phology and mitochondrial fission in the liver of both
Bmal1flox/flox and Bmal1-MKO mice (Supporting Fig.
S5F). Taken together, BMAL1 in macrophages is likely




INDUCED FATTY LIVER AND
LIVER INJURY
So far, we have demonstrated that lack of BMAL1
expression is detrimental to hepatocytes when chal-
lenged by ethanol feeding. It remains unclear whether
over-expression of BMAL1 is sufficient to protect mice
from ALDs. Female WT mice were injected with either
Ad-GFP or Ad-Bmal1 prior to alcohol feeding/binge
treatment. We first verified BMAL1 over-expression in
the liver by immunoblotting with anti-FLAG. Over the
course of alcohol feeding, mice injected with Ad-GFP
showed similar body weight as mice with Ad-Bmal1
(Supporting Fig. S6A). However, Ad-Bmal1 injected
mice showed approximately 50% reduction in liver TG
content, which was further supported by H&E staining
and Nile-Red staining (Fig. 3A,B). Moreover, Ad-
Bmal1 expressing mice showed reduced serum ALT,
suggesting BMAL1 over-expression protects mice
against ethanol-induced liver injury (Fig. 3C). More-
over, BMAL1 over-expression led to enhanced AKT-
PS473 phosphorylation in the liver of alcohol-fed female
mice (Fig. 3D). To determine whether this protection
against ethanol-induced liver injury is gender-specific,
we also assessed liver steatosis and injury in ethanol-fed
male WT mice after injection of Ad-Bmal1. As shown
in Supporting Fig. S6, BMAL1 overexpression indeed
effectively reduced serum ALT, but to a lesser degree
liver steatosis in male WT mice after ethanol feeding.
Together these data support that ectopic expression of
BMAL1 in the liver is sufficient to protect mice from
alcohol feeding-induced fatty liver and liver injury.
What is the underlying mechanism for the protec-
tive role of BMAL1? Given the role of BMAL1 as a
key regulator of the circadian clock, we first examined
the expression of BMAL1 targets in the liver of Ad-
Bmal1-injected female mice following alcohol feeding.
To our surprise, we only detected modest induction of
Dbp, Nr1d1, and Per2 in the liver (Fig. 3E). In con-
trast, we observed robust induction of lipogenic genes
(Fasn, Acc1, and Scd1) and the glycolytic gene Lpk
(Fig. 3F). Moreover, the expression of genes in ER
stress, apoptosis, and oxidative stress were comparable
between Ad-GFP and Ad-Bmal1 group (Supporting
Fig. S7). These data suggest that BMAL1 overexpres-
sion may protect mice against ALD in part via its
ability to regulate hepatic lipid metabolism, particularly
de novo lipogenic pathway.
HEPATOCYTE BMAL1 PROTECTS
ALD VIA PROMOTING PPARa-
MEDIATED b-OXIDATION
We further investigated how BMAL1 could impact
hepatic lipid metabolism during the pathogenesis of
ALD. Previously, we discovered that hepatocyte
BMAL1 is required for post-prandial de novo lipogen-
esis,(7) while others reported that BMAL1 regulates
the PPARa expression and fatty acid oxidation in hep-
atocytes.(24,25) Dysregulated hepatic lipid metabolism
is one of major pathological feature of ALD, which is
characterized by increased de novo lipogenesis and sup-
pressed fatty acid oxidation. We therefore hypothesize
that BMAL1 may protect hepatocytes against ethanol
toxicity by maintaining lipid homeostasis in the liver.
We first measured the mRNA expression of lipid
metabolism in the mouse liver with various levels of
Bmal1 expression following ethanol feeding. Compared
with Bmal1flox/flox mice, we observed reduced expression
of genes in de novo lipogenesis and fatty acid oxidation
in Bmal1-LKO liver (Fig. 4A,B). A similar down-
regulation of de novo lipogenesis and fatty acid oxidation
genes in Ad-shBmal1-injected liver was also observed
vs. Ad-shLacZ mice (Fig. 4D,E), suggesting that
Bmal1 deficiency leads to a suppression of both de novo
lipogenesis and fatty acid oxidation pathways.
Previous studies demonstrated that Ppara knockout
mice are more sensitive to ethanol-induced liver
injury.(26) We suspected that suppression of the
PPARa pathway contributes to the severity of ALD in
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Bmal1-LKO and hepatic Bmal1-depleted mice.
Although we detected about 40% and 20% reduction
of Ppara mRNA in the Bmal1-LKO and Bmal1-
depleted liver respectively, the PPARa protein
abundance in the liver was comparable between
Bmal1flox/flox and Bmal1-LKO mice or between Ad-
shLacZ and Ad-shBmal1 mice (Fig. 4C,F), suggesting
that BMAL1 may regulate the biogenesis of endoge-
nous ligands for PPARa without affecting its protein
abundance. Thus, we speculated that supplementation
of synthetic PPARa ligands could ameliorate ALD in
Bmal1-LKO mice. As a synthetic PPARa agonist,
fenofibrate has been clinically used to treat hyperlipid-
emia.(27,28) Of note, we firstly used ethanol-fed WT
mice to confirm the efficacy of fenofibrate. At the
dose of 20 mg/kg, daily treatment of fenofibrate was
sufficient to reduce liver steatosis and serum ALT
(Supporting Fig. S8), consistently with the previous
report.(29) We therefore tested our hypothesis by treat-
ing Bmal1-LKO mice daily with either corn oil or
fenofibrate during the course of ethanol feeding. As
expected, fenofibrate stimulated the expression of
PPARa target genes in the liver of Bmal1-LKO mice
such as Acox1, Cpt1a, and Cyp4a10 (Fig. 5A). Fenofi-
brate treatment reduced lipid accumulation in the liver
of Bmal1-LKO mice (Fig. 5B,C). Additionally, fenofi-
brate lowered serum ALT and reduced TUNEL-
positive hepatocytes (Fig. 5D,E). Electron microscopy
also showed higher density of mitochondria in active
fission in the liver of fenofibrate-treated Bmal1-LKO
mice (Fig. 5F). Taken together, we found that reacti-
vation of PPARa signaling by fenofibrate could reverse
liver steatosis, liver injury, and mitochondrial impair-
ment in ethanol-fed Bmal1-LKO mice.
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FIG. 3. Liver-specific Bmal1 over-expression protects mice from alcohol feeding-induced fatty liver and liver injury. Eight-week-old
mice were injected with adenovirus expressing either Bmal1 (Ad-Bmal1, n 5 8) or GFP control (Ad-GFP, n 5 5), and then fed 5%
ethanol diet for 10 days and binged with 5 g ethanol per kg body weight at ZT3 of the eleventh day and were dissected 9 hours later.
(A,B) Bmal1 overexpression lowers ethanol-induced liver toxicity. Hepatic triglycerides assay (A), H&E staining and Nile red staining
(B) were utilized to assess hepatic lipid accumulation. Liver injury was assessed with ALT assay (C). (D-F) Bmal1 overexpression
activates hepatic lipogenesis. AKT phosphorylation was assessed with western blotting (D). Circadian genes (E) and lipogenic genes
(F) were assessed with RT-qPCR. *p < 0.05, ***p < 0.001 by two-tailed Student’s t test. Scale bar 5 100 uM.
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CONSTITUTIVELY ACTIVE AKT
RESTORES PPARa ACTIVITY AND
REVERSES LIVER INJURY IN
ETHANOL DIET-FED Bmal1-LKO
MICE
Hepatocyte PPARa signaling plays an essential role
in maintaining lipid homeostasis in the liver. PPARa
activity is dynamically regulated by nutritional status
and various hormonal inputs. It is thought that
PPARa activity elevates during fasting and becomes
suppressed by feeding. Unexpectedly, hepatocyte-
specific Fasn knockout mice show reduced PPARa
activity and liver steatosis, suggesting a positive cross-
talk between hepatic de novo lipogenesis and PPARa-
mediated fatty acid oxidation.(12) It has been proposed
that hepatic lipogenesis may be responsible for de novo
biogenesis of endogenous PPARa ligands.(12,13,30) We
also demonstrated previously that restoring AKT activ-
ity by expressing constitutively active AKT2 (AKT2-
CA) can rescue the defect of de novo lipogenesis in the
Bmal1 knockout liver.(7) Since de novo lipogenesis and
PPARa pathways were both repressed in the ethanol-
fed Bmal1-LKO mice, we investigated whether
BMAL1-driven de novo lipogenesis pathway could
impact the PPARa transcription activity. To test this
hypothesis, we first determined whether restoring
cellular AKT could induce PPARa target genes in
hepatocytes with Bmal1 deficiency. In Bmal1-LKO
hepatocytes, over-expression of AKT2-CA increased
the expression of not only lipogenic genes but also a
subset of b-oxidation genes (Supporting Fig. S9). To
test how AKT2-CA overexpression in the liver affects
PPARa target gene expression in Bmal1-LKO, we
injected Bmal1-LKO mice with either Ad-GFP or
Ad-Akt2-CA prior to ethanol feeding. Overexpression
                                                                                                                                      
FIG. 4. Hepatic Bmal1 deficiency results in decreased gene expression of both de novo lipogenesis and b-oxidation in the liver of
ethanol-fed mice. (A-C) Hepatocyte-specific deficiency of Bmal1 results in decreased PPARa activity in BLKO mice liver after ethanol
treatment. Mice were treated as described in Fig. 1. Relative mRNA levels of lipogenic genes (A) and PPARa target genes (B), and
protein levels of PPARa (C) in the livers of Bmal1-LKO mice (n55), were compared to those of Bmal1Flox/Flox mice (n54). (D-F)
Adult-onset Bmal1 depletion in the liver decreases the PPARa activity after ethanol treatment. Relative mRNA levels of lipogenic
genes (D) and PPARa target genes (E), and protein levels of PPARa (F) in the livers of Ad-shBmal1-injected mice (n58), were
compared with those of Ad-shLacZ control (n55). *p < 0.05, ***p < 0.001 by two-tailed Student’s t test.
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of AKT2-CA was confirmed by immunoblotting for
total AKT2 and GSK3b-PS9, a direct phosphorylation
target of AKT (Fig. 6A). In ethanol-fed Bmal1-LKO
mouse livers, over-expression of AKT2-CA induced
lipogenic genes, and more importantly, increased
several PPARa targets (Fig. 6B). Notably, over-
expression of AKT2-CA showed stronger effects on
PPARa targets in vivo than in primary hepatocytes,
possibly due to a longer duration of expression.
Next, we examined the impact of AKT2-CA over-
expression on the severity of ALD in BLKO mice.
H&E staining and Nile-Red staining showed reduced
lipid accumulation in the liver of AKT2-CA injected
mice (Fig. 6C,D) in addition to reduced liver TG (Fig.
6E). Restoring of AKT activity also reduced liver injury
detected by lower ALT level (Fig. 6F), fewer TUNEL-
positive cells and reduced caspase 3 cleavage (Support-
ing Fig. S10A,B). Interestingly, the protective effects of
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FIG. 5. Fenofibrate administration rescues ethanol-induced liver injury in BLKO mice. Eight-week-old BLKO mice were fed 5% eth-
anol diet for 10 days. From the third day of ethanol diet feeding, mice were gavaged daily with fenofibrate (20 mg/ kg body weight)
till the last day of ethanol diet feeding. On the eleventh day, mice were binged with 5g ethanol/kg body weight at ZT3, and were dis-
sected 9 hours later (n 5 5 for control and n 5 7 for fenofibrate, both males and females). (A) PPARa activation by fenofibrate was
confirmed by the induction of PPARa target genes with RT-qPCR. (B,C) Fenofibrate treatment reduces ethanol feeding-induced liver
steatosis in Bmal1-LKO mice, assessed by H&E staining and Oil-Red-O staining (B) and liver triglycerides assay (C). (D-F) Fenofi-
brate treatment ameliorates ethanol-induced liver injury in Bmal1-LKO mice. Liver injury was assessed with ALT assay (D), TUNEL
staining (E) and electron microscopy (magnification 40,000X) (F). Mitochondria undergoing fission were indicated with green arrow-
heads, and swollen mitochondria with red arrowheads. *p < 0.05, **p < 0.01 by two-tailed Student’s t test. Scale bar 5 100 uM for
B and E; Scale bar 5 400 nM for F.
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AKT2-CA overexpression were only observed in
Bmal1-LKO liver but not in WT mice (Fig. 6F, Sup-
porting Fig. S11). Taken together, restoring hepatocyte
AKT is sufficient to reverse ALD in Bmal1-LKO mice.
Furthermore, increasing AKT activity in Bmal1-LKO
mice not only promotes de novo lipogenesis but also
enhances the expression of b-oxidation genes. To our
knowledge this is the first evidence showing that active
AKT signaling pathway enhances both de novo lipogen-
esis and b-oxidation while protecting against ALD.
OVEREXPRESSION OF ChREBP IN
THE LIVER PARTIALLY RESCUES
LIVER INJURY IN ETHANOL-FED
Bmal1-LKO MICE
Both ChREBP and SREBP-1c are two major
lipogenic transcription factors in hepatic lipid
biosynthesis.(31) SREBP-1c has been implicated as a
direct downstream effector of AKT-mTORC1 signal-
ing in insulin-induced de novo lipogenesis,(32) whereas
ChREBP has been more associated with high carbo-
hydrate feeding, in particular, fructose feeding.(33,34) A
recent study showed loss of Chrebp may sensitize mice
from binge-drinking-induced liver injury.(35) We
observed that L-pk, the hallmark target of ChREBP,
was reduced in the liver of both Bmal1-LKO and mice
with liver specific depletion of Bmal1 but induced in
Ad-Bmal1 liver (Fig. 3F, Fig. 4A,D), indicating a
functional link between BMAL1 and ChREBP during
the process of de novo lipogenesis. Furthermore, we
evaluated the effects of ChREBP over-expression in
primary hepatocyte isolated from Bmal1flox/flox and
Bmal1-LKO mice on the expression of enzymes in
lipogenesis and fatty acid oxidation. We also included
SREBP-1c as a comparison. Consistent with their
                                                                                                                                      
FIG. 6. Restoring AKT activity rescues both de novo lipogenesis and PPARa pathway and reverses liver injury in Bmal1-LKO mice.
Eight-week-old Bmal1-LKO mice were injected with Ad-Akt2-CA (n 5 6) or Ad-GFP (n 5 5), and then fed 5% ethanol diet for
10 days, binged with 5g ethanol/kg body weight at ZT3 on the eleventh day, and were dissected 9 hours later. (A) AKT2 activity was
confirmed by western blotting with anti-AKT2 and anti-GSK3b phosphorylation. (B) Restoring AKT activity induces both de novo
lipogenic genes and b-oxidation genes with RT-qPCR. (C-F) AKT activation reduces ethanol-induced liver steatosis and injury in
Bmal1-LKO mice with H&E staining (C) and Nile Red staining (D), liver triglycerides assay (E) and serum ALT assay (F). *p <
0.05, **p < 0.01 by two-tailed Student’s t test. Scale bar 5 100 lM.
                                                                                                                                      
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roles in driving de novo lipogenesis, both SREBP-1c
and ChREBP overexpression significantly induced key
genes of lipogenic program (Supporting Fig. S12A,C).
However, only ChREBP was able to potently induce
the expression of b-oxidation genes (Supporting Fig.
S12B,D). Of note, compared with Bmal1flox/flox hepa-
tocytes, Bmal1-LKO hepatocytes showed a more
robust induction of b-oxidation genes in response to
ChREBP overexpression. These data unveiled a
diverging effect of ChREBP and SREBP-1c on b-
oxidation in the liver.
These observations prompted us to ask whether
over-expression of ChREBP in liver could affect the
degree of liver injury in ethanol-fed Bmal1-LKO mice.
Over-expression of FLAG-ChREBP in the liver after
Ad-Flag-Chrebp adenovirus injection was confirmed by
immunoblotting with anti-FLAG (Fig. 7A). Compared
with Ad-GFP injection, Ad-Flag-Chrebp injection
induced hepatic expression of b-oxidation genes (Fig.
7B), reduced fat accumulation in the liver of Bmal1-
LKO mice (Fig. 7C-E). We also detected significantly
reduced apoptosis in the liver in addition to modestly
decreased serum ALT (Supporting Fig. S13). Interest-
ingly, the protective effect of ChREBP overexpression
was only observed in the Bmal1-LKO liver but not in
that of WT mice (Supporting Fig. S14).
                                                                                                                                      
FIG. 7. Hepatic overexpression of ChREBP restores the PPARa activity and partially ameliorates liver injury in ethanol-fed Bmal1-
LKO mice. Eight-week-old Bmal1-LKO mice were injected with Ad-Flag-Chrebp (n 5 5) or Ad-GFP (n 5 3), and then fed 5% eth-
anol diet for 10 days and binged with ethanol 5g/kg body weight at ZT3, and were dissected 9 hours later. (A) Hepatic ChREBP
overexpression by adeovirus was confirmed by immunoprecipitation with anti-FLAG beads and western blotting with anti-FLAG. (B)
Hepatic ChREBP overexpression activates the expression of L-pk and PPARa target genes measured by RT-qPCR. (C-E) Hepatic
ChREBP overexpression reduces ethanol feeding-induced liver steatosis in Bmal1-LKO mice with liver triglycerides assay (C) H&E
staining (D) and Nile Red staining (E). (E,F) Hepatic ChREBP overexpression ameliorates ethanol-induced liver injury in Bmal1-
LKO mice with serum ALT assay (E). (F) Model depicting that BMAL1 limits ethanol-induced lipotoxicity via increased b-oxidation
by activating de novo lipogenesis to provide ligands for PPARa. *p < 0.05, by two-tailed Student’s t test. Scale bar 5 100 lM
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Meanwhile, we also evaluated whether over-
expression of SREBP-1c in the liver could impact the
degree of liver injury in ethanol-fed Bmal1-LKO mice.
As shown in Supporting Fig. S15B-D, ectopic expres-
sion of SREBP-1c failed to reduce liver steatosis and
liver injury after ethanol diet. Moreover, SREBP-1c
overexpression reduced the expression of b-oxidation
genes in ethanol-fed Bmal1-LKO mice (Supporting
Fig. S15E). In summary, these data suggest that
ChREBP overexpression in the Bmal1-LKO liver effi-
ciently reverses alcoholic fatty liver and reduces liver
injury. Our study also demonstrated a clear distinction
between ChREBP and SREBP-1c in hepatic regula-
tion of de novo lipogenesis and fatty acid oxidation
during ethanol feeding.
To investigate the clinical relevance of the BMAL1-
AKT-ChREBP axis in human ALD, we examined
the abundance of BMAL1, AKT-PS473, AKT, and
ChREBP in the liver samples from patients with alco-
holic hepatitis vs. normal controls. Indeed, BMAL1
protein levels were severely decreased in the livers of
patients with ALD compared with normal controls
(Supporting Fig. S16). In the same liver samples, the
levels of AKT-PS473 were greatly reduced. Moreover,
ChREBP protein levels were reduced in the liver of
ALD patients. Collectively, our data suggest that the
impairment of the BMAL1-AKT-ChREBP axis
could be involved in the development of human ALD.
Discussion
In the current study, we presented evidence support-
ing that the intact circadian clock in the liver is
required to protect mice from ethanol feeding-induced
liver steatosis and injury. Either chronic or acute loss
of Bmal1 aggravates liver steatosis and injury after
chronic ethanol-binge feeding. Impaired PPARa sig-
naling may drive the severity of ALD in the Bmal1-
deficient condition since PPARa agonist fenofibrate
rescues liver injury in Bmal1-LKO mice. Further inves-
tigations reveal an intimate relationship between the
BMAL1-AKT-ChREBP axis-mediated de novo lipo-
genesis and PPARa-induced fatty acid oxidation. In
summary, our work demonstrated a pivotal role of the
circadian clock protein BMAL1 in the liver in protect-
ing against ALD via maintaining hepatic lipid
homeostasis.
Recent studies suggest a potential crosstalk between
alcohol metabolism and circadian rhythms could
impact the progression and severity of ALD.(4,36)
We observed severe liver steatosis and liver injury fol-
lowing ethanol feeding in two different mouse models
with circadian clock deficiency in the liver, pointing to
the protective role of an intact hepatic circadian clock
against ALD. Interestingly, our study revealed that it
is the circadian clock in hepatocytes rather than macro-
phages that protects the liver in response to ethanol
feeding, highlighting the cell type-specific function of
the circadian clock. Our data suggest that hepatic cir-
cadian deficiency or impairment could be a risk factor
for the development of advanced ALD. It has been
reported that high-fat diet greatly dampens the hepatic
circadian clock even before the development of obe-
sity.(37) Social factors such as jet-lag can also disturb
the hepatic circadian clock.(16) Therefore, restoring or
maintaining a normal circadian clock could be key to
the prevention or treatment of ALD.
Our study also suggests that BMAL1 overexpres-
sion is also sufficient in protecting mice from alcoholic
liver injury. Liver-specific expression of BMAL1 using
adenovirus provides almost full protection against
ALD in both female and male mice. This exciting
finding suggests that elevating the BMAL1 abundance
in hepatocytes might be an effective approach to treat
ALD. In our study, we also found that BMAL1 pro-
tein is modestly increased in the liver of ethanol-fed
WT mice although the clock activity is suppressed. It
is well known that the Bmal1 mRNA oscillates in hep-
atocytes during a 24-hr cycle and multiple transcrip-
tion factors are implicated in its mRNA oscillation. In
contrast, the BMAL1 protein levels remain steady
with modest changes throughout the circadian
cycle.(38) It has been suggested that BMAL1 protein
abundance and activity are subject to multiple post-
translational modifications including O-linked glyco-
sylation, acetylation, and phosphorylation.(38-41) We
suspect that elevated BMAL1 protein in the ethanol-
fed WT mouse liver is a net result of altered multiple
upstream signaling pathways. Given that BMAL1
overexpression is sufficient to protect mice from ALD,
the modest induction of BMAL1 in the liver of
ethanol-fed WT mice might be a compensatory mech-
anism to preserve the clock activity in hepatocytes.
Based on our findings, one of the major downstream
pathways could be AKT-ChREBP-lipogenesis.
During ethanol feeding, BMAL1 over-expression up-
regulates liver AKT activity and ChREBP target gene
expression, whereas Bmal1 deficiency reduces liver
AKT activation and ChREBP target gene expression.
Restoring AKT or ChREBP in Bmal1-LKO mice
attenuates fatty liver and more importantly activates
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the b-oxidation pathway. How BMAL1 regulates the
ChREBP transcriptional activity via AKT remains to
be determined in future study. A recent study suggests
AKT can activate ChREBP in brown adipose tissue
upon cold exposure.(42) It is intriguing to speculate
that a similar pathway is conserved in hepatocytes in
the context of ethanol feeding.
Our findings have shed light on an under-
appreciated function of hepatocyte de novo lipogenesis
in promoting PPARa-dependent b-oxidation path-
way. The Semenkovich group used hepatocyte-specific
Fasn
concept that de novo lipogenesis in hepatocytes pro-
motes PPARa and b-oxidation pathway by generating
newly synthesized PPARa-specific ligands.(12,13) For
alcoholic fatty liver disease, a canonical model is that
lipogenesis over-activation leads to liver steatosis and
lipotoxicity. However, a recent report showed that
although ethanol feeding induced liver steatosis in
mice, lipogenic gene expression was repressed.(43) Our
findings support this concept in Bmal1-LKO mice by
demonstrating hepatic BMAL1 acts as a central regu-
lator that coordinates de novo lipogenesis and PPARa-
dependent b-oxidation in hepatocytes when challenged
with ethanol feeding. Given the fact that BMAL1,
ChREBP, and SREBP-1c all can stimulate the tran-
scriptional program of de novo lipogenesis, it will be
interesting to use unbiased lipodomics to differentiate
lipid end-products specific for each lipogenic factor
after over-expression.
The Bailey group showed that chronic ethanol con-
sumption disrupts the core circadian clock and diurnal
rhythms of metabolic genes in the liver.(44) The Duf-
field group also showed the circadian clock impairment
in the mouse liver with alcohol–induced steatosis.(45)
In agreement with these two studies, our study showed
disrupted diurnal rhythms of core clock genes and a
potent suppression of SIRT1 activity in the ethanol-
fed mouse liver. Compared with the two studies, our
study used a different chronic feeding/binge protocol.
Therefore, there are noticeable differences in the type
and pattern of clock genes oscillations affected by the
duration of feeding, degree of liver steatosis, and sever-
ity of injury. It is likely that ethanol feeding impacts
the expression of circadian genes in both clock-
dependent and clock-independent manners.
In summary, we have presented evidence that
BMAL1, a key circadian protein, is both necessary and
sufficient to protect mice against ALD. Our findings
identified the BMAL1-AKT-ChREBP-lipogenesis
axis as a major signaling route in the pathogenesis of
ALD. Our study suggests that activation of BMAL1-
dependent de novo lipogensis in the liver could offer
therapeutics to treat human ALD.
Acknowledgement: We thank Dr. Jiandie Lin (Univer-
sity of Michigan) for providing Bmal1flox/flox mice.
REFERENCES
1) Massey VL, Arteel GE. Acute alcohol-induced liver injury. Front
Physiol 2012;3:193.
2) Poppitt SD. Beverage Consumption: Are Alcoholic and Sugary
Drinks Tipping the Balance towards Overweight and Obesity?
Nutrients 2015;7:6700-6718.
3) Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of
injury and targeted treatment. Nat Rev Gastroenterol Hepatol
2015;12:231-242.
4) Summa KC, Voigt RM, Forsyth CB, Shaikh M, Cavanaugh K,
Tang Y, et al. Disruption of the circadian clock in mice increases
intestinal permeability and promotes alcohol-induced hepatic
pathology and inflammation. PloS One 2013;8:e67102.
5) Swanson GR, Gorenz A, Shaikh M, Desai V, Kaminsky T, Van
Den Berg J, et al. Night workers with circadian misalignment are
susceptible to alcohol-induced intestinal hyperpermeability with
social drinking. Am J Gastrointest Liver Physiol 2016;311:
G192-G201.
6) Asher G, Sassone-Corsi P. Time for food: the intimate interplay
between nutrition, metabolism, and the circadian clock. Cell
2015;161:84-92.
7) Zhang D, Tong X, Arthurs B, Guha A, Rui L, Kamath A, et al.
Liver clock protein BMAL1 promotes de novo lipogenesis
through insulin-mTORC2-AKT signaling. J Biol Chem 2014;
289:25925-25935.
8) Jacobi D, Liu S, Burkewitz K, Kory N, Knudsen NH, Alexander
RK, et al. Hepatic Bmal1 regulates rhythmic mitochondrial
dynamics and promotes metabolic fitness. Cell metab 2015;22:
709-720.
9) Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome
proliferator-activated receptor a (PPARa) agonist treatment
reverses PPARa dysfunction and abnormalities in hepatic lipid
metabolism in ethanol-fed mice. J Biol Chem 2003;278:27997-
28004.
10) Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The tran-
scriptional and dna binding activity of peroxisome proliferator-
activated receptor a is inhibited by ethanol metabolism. a novel
mechanism for the development of ethanol-induced fatty liver.
J Biol Chem 2001;276:68-75.
11) You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces
fatty acid synthesis pathways by activation of sterol regulatory
element-binding protein (SREBP). J Biol Chem 2002;277:
29342-29347.
12) Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG,
Coleman T, et al. “New” hepatic fat activates PPARa to main-
tain glucose, lipid, and cholesterol homeostasis. Cell Metab
2005;1:309-322.
13) Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE,
Turk J, et al. Identification of a physiologically relevant endoge-
nous ligand for PPARa in liver. Cell 2009;138:476-488.
13895
ZHANG ET AL.Hepatology, Vol. 68, No. 3, 2018
knockout  mice  as  a  model  to  establish a
14) Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model
of chronic and binge ethanol feeding (the NIAAA model). Nat
Protoc 2013;8:627.
15) Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. Micro-
RNA-217 promotes ethanol-induced fat accumulation in hepato-
cytes by down-regulating SIRT1. J Biol Chem 2012;287:9817-
9826.
16) Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C,
Kreppel F, et al. SIRT1 regulates circadian clock gene expression
through PER2 deacetylation. Cell 2008;134:317-328.
17) Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J,
Chen D, et al. The NAD1-dependent deacetylase SIRT1 mod-
ulates CLOCK-mediated chromatin remodeling and circadian
control. Cell 2008;134:329-340.
18) Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P.
Circadian control of the NAD1 salvage pathway by CLOCK-
SIRT1. Science 2009;324:654-657.
19) Tong X, Zhang D, Arthurs B, Li P, Durudogan L, Gupta N,
et al. Palmitate inhibits SIRT1-dependent BMAL1/CLOCK
interaction and disrupts circadian gene oscillations in hepatocytes.
PloS One 2015;10:e0130047.
20) Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a
dysfunctional relationship. Gastroenterology 2002;122:2049-2063.
21) Mehta AJ, Guidot DM. Alcohol abuse, the alveolar macrophage
and pneumonia. Am J Med Sci 2012;343:244-247.
22) Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y,
et al. Alcohol stimulates macrophage activation through caspase-
dependent hepatocyte derived release of CD40L containing
extracellular vesicles. J Hepatol 2016;64:651-660.
23) Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of
the immune system. Nat Rev Immunol 2013;13:190-198.
24) Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS,
Michalik L, et al. Reciprocal regulation of brain and muscle
Arnt-like protein 1 and peroxisome proliferator-activated receptor
a defines a novel positive feedback loop in the rodent liver circa-
dian clock. Mol Endocrinol 2006;20:1715-1727.
25) Oishi K, Shirai H, Ishida N. CLOCK is involved in the circa-
dian transactivation of peroxisome-proliferator-activated receptor
a (PPARa) in mice. Biochem 2005;386:575-581.
26) Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E,
Kiyosawa K, et al. Peroxisome proliferator-activated receptor a
protects against alcohol-induced liver damage. HEPATOLOGY
2004;40:972-980.
27) Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M.
Mechanisms of the triglyceride-and cholesterol-lowering effect of
fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes
2002;51:3486-3491.
28) Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-
Garcia AB, et al. Effects of adding fenofibrate (200 mg/day) to
simvastatin (10 mg/day) in patients with combined hyperlipid-
emia and metabolic syndrome. American J Cardiol 2003;91:956-
960.
29) Tsutsumi M, Takase S. Effect of fenofibrate on fatty liver in rats
treated with alcohol. Alcohol Clin Exp Res 2001;25(6 Suppl):
75S-89S.
30) Liu S, Alexander RK, Lee C-H. Lipid metabolites as metabolic
messengers in inter-organ communication. Trends Endocrinol
Metab 2014;25:356-363.
31) Zhang D, Yin L. Transcriptional Regulation of De Novo Lipo-
genesis in Liver. In: Ntambi, J, ed. Hepatic De Novo
Lipogenesis and Regulation of Metabolism. 1st ed. Switzerland:
Springer; 2016;1-31.
32) Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI,
et al. Akt stimulates hepatic SREBP1c and lipogenesis through
parallel mTORC1-dependent and independent pathways. Cell
Metab 2011;14:21-32.
33) Zhang DQ, Tong X, VanDommelen K, Gupta N, Stamper K,
Brady GF, et al. Lipogenic transcription factor ChREBP medi-
ates fructose-induced metabolic adaptations to prevent hepatotox-
icity. J Clin Invest 2017;127.
34) Abdul-Wahed A, Guilmeau S, Postic C. Sweet Sixteenth for
ChREBP: Established Roles and Future Goals. Cell Metab
2017;26:324-341.
35) Marmier S, Dentin R, Daujat-Chavanieu M, Guillou H,
Bertrand-Michel J, Gerbal-Chaloin S, et al. Novel role for carbo-
hydrate responsive element binding protein in the control of
ethanol metabolism and susceptibility to binge drinking.
HEPATOLOGY 2015;62:1086-1100.
36) Udoh US, Valcin JA, Gamble KL, Bailey SM. The molecular
circadian clock and alcohol-induced liver injury. Biomolecules
2015;5:2504-2537.
37) Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C,
Kobayashi Y, et al. High-fat diet disrupts behavioral and molecu-
lar circadian rhythms in mice. Cell Metab 2007;6:414-421.
38) Li MD, Ruan HB, Hughes ME, Lee JS, Singh JP, Jones SP, et al.
O-GlcNAc signaling entrains the circadian clock by inhibiting
BMAL1/CLOCK ubiquitination. Cell Metab 2013;17:303-310.
39) Hirayama J, Sahar S, Grimaldi B, Tamaru T, Takamatsu K,
Nakahata Y, et al. CLOCK-mediated acetylation of BMAL1
controls circadian function. Nature 2007;450:1086-1090.
40) Sahar S, Zocchi L, Kinoshita C, Borrelli E, Sassone-Corsi P.
Regulation of BMAL1 protein stability and circadian function by
GSK3b-mediated phosphorylation. PloS One 2010;5:e8561.
41) Tamaru T, Hirayama J, Isojima Y, Nagai K, Norioka S,
Takamatsu K, et al. CK2a phosphorylates BMAL1 to regulate
the mammalian clock. Nat Struc Mol Biol 2009;16:446-448.
42) Sanchez-Gurmaches J, Tang Y, Jespersen NZ, Wallace M, Martinez
Calejman C, Gujja S, et al. Brown fat AKT2 is a cold-induced kinase
that stimulates ChREBP-mediated de novo lipogenesis to optimize fuel
storage and thermogenesis. CellMetab 2018;27:195-209.
43) Yang Z, Tsuchiya H, Zhang Y, Lee S, Liu C, Huang Y, et al.
REV-ERBa activates C/EBP homologous protein to control
small heterodimer partner–mediated oscillation of alcoholic fatty
liver. American J Pathol 2016;186:2909-2920.
44) Filiano AN, Millender-Swain T, Johnson R Jr, Young ME,
Gamble KL, Bailey SM. Chronic ethanol consumption disrupts
the core molecular clock and diurnal rhythms of metabolic genes
in the liver without affecting the suprachiasmatic nucleus. PloS
One 2013;8:e71684.
45) Zhou P, Ross RA, Pywell CM, Liangpunsakul S, Duffield GE.
Disturbances in the murine hepatic circadian clock in alcohol-
induced hepatic steatosis. Sci Rep 2014;4:3725.
Authors names in bold designate shared co-first authorship.
Supporting Information
Additional Supporting Information may be found at
onlinelibrary.wiley.com/doi/10.1002/hep.29878/suppinfo.
14896
ZHANG ET AL. Hepatology, September 2018
